- 건국대학교

	Prof. Chankyu Park’s Research is Selected as Top 100 Achievements of 2020 National Research Development
	관리자		579		2020.11.04

<img width="202" height="255" style="float: left; margin-left: 10px; margin-right: 10px;" src="ArticleFile.do?id=11799704" />
A Research achievement of Professor Chankyu Park from Department of Stell Cell and Regenerative Biotechnology at Konkuk University’s Konkuk Institute of Science and Technology(KIT) ranked among ‘Top 100 Achievements of 2020 National Research Development’ selected by Ministry of Science and ICT on the 29th. (Research title: Development of antibiotic replacement therapy and high-efficiency vaccine production technology through application of high-efficiency production technology of antibacterial and bacterial toxin peptide)
Antibacterial peptide is a congenital immune substance which is used for most organisms including animals and plants to protect themselves from external danger. It is gaining attention as a next-generation antibiotic that can solve the resistance problem since it shows great antibacterial activity even for bacteria that are resistant to existing antibiotics.
Bacterial toxin peptide is a substance that provokes symptoms for bacterial infection. Although there is no vaccine development for the substance and is on the market, it is necessary to develop high-efficiency vaccines using toxins and pathogen diagnosis technologies.
Due to high production costs, it has been difficult to mass-produce antibacterial and bacterial toxin peptides until now, and has not been able to develop genetically engineered technologies which can be applied industrially. The research team led by Professor Park has developed the world's best genetic engineering mass production technology that can express antibacterial and bacterial toxin proteins at high efficiency through colon bacillus expression system using engineered Green Fluorescence Protein (GFP), and applied for patents on source technology in the United States, Europe and China. <img width="650" height="339" style="margin-left: auto; display: block; margin-right: auto;" alt="" src="ArticleFile.do?id=11799705" /> 
The research team has secured production efficiency ten times more than that of existing technology by upgrading the new technology into a core industrialization platform technology (pilot scale) based on a bioreactor. The developed industrialization technology is planned to be applied in the development of antibiotic substitutes and high-efficiency vaccine for safety management and productivity improvement of animal resources.
The technology transfer of industrial technology was completed through the research with one case of industrialization platform of antibacterial and bacterial toxin peptide developed and two other cases of the high efficiency vaccine production for pig edema and pleura pneumonia.
Professor Park said, “The core platform technology developed through this research is a world-class technology that has applied for international patents in the United States, Europe, and China,” and “Despite the limitation to overcome before it can be used as human medicine, we will make continuous efforts to industrialize the technology through various researches.”
 <img width="660" height="455" style="margin-left: auto; display: block; margin-right: auto;" alt="" src="ArticleFile.do?id=11799706" /> <img width="594" height="409" style="margin-left: auto; display: block; margin-right: auto;" alt="" src="ArticleFile.do?id=11799707" /> <img width="608" height="463" style="margin-left: auto; display: block; margin-right: auto;" alt="" src="ArticleFile.do?id=11799708" /> <img width="586" height="335" style="margin-left: auto; display: block; margin-right: auto;" alt="" src="ArticleFile.do?id=11799709" />


	Prof. Changseon Song’s Resear...
	KU Research Team and KITECH D...